The distinctive clinical features of paraneoplastic sensory neuronopathy

C. H. Chalk, Anthony John Windebank, D. W. Kimmel, P. G. McManis

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

A 15-year experience with paraneoplastic sensory neuronopathy at the Mayo Clinic is reviewed. Of 26 patients with paraneoplastic sensory neuronopathy, 19 had small cell lung cancer, 4 had breast cancer, and 3 had other neoplasms. There was a striking predominance of females (20:6). Neuropathic symptoms (pain, paresthesia, sensory loss) were asymmetric at onset, with a predilection for the upper limbs; in three patients, symptoms were confined to the arms. Electrophysiologic testing revealed absent sensory responses and normal or minimally altered motor responses. Slightly more than half the patients had associated autonomic, cerebellar, or cerebral abnormalities. In some patients, treatment of the neoplasm seemed to halt progression of the neuronopathy, but none had neurologic improvement and most continued to worsen, even when the oncologic response was good. Distinguishing between paraneoplastic and nonparaneoplastic sensory neuronopathies can be difficult, but prominent neuropathic pain, neurologic dysfunction involving more than the peripheral sensory system, or an increased cerebrospinal fluid protein value should prompt a careful search for a cancer.

Original languageEnglish (US)
Pages (from-to)346-351
Number of pages6
JournalCanadian Journal of Neurological Sciences
Volume19
Issue number3
StatePublished - 1992

Fingerprint

Neuralgia
Cerebrospinal Fluid Proteins
Neoplasms
Paresthesia
Small Cell Lung Carcinoma
Neurologic Manifestations
Upper Extremity
Nervous System
Arm
Therapeutics
Breast Cancer 3

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

The distinctive clinical features of paraneoplastic sensory neuronopathy. / Chalk, C. H.; Windebank, Anthony John; Kimmel, D. W.; McManis, P. G.

In: Canadian Journal of Neurological Sciences, Vol. 19, No. 3, 1992, p. 346-351.

Research output: Contribution to journalArticle

@article{c2091beb1143474fabed5992e569c975,
title = "The distinctive clinical features of paraneoplastic sensory neuronopathy",
abstract = "A 15-year experience with paraneoplastic sensory neuronopathy at the Mayo Clinic is reviewed. Of 26 patients with paraneoplastic sensory neuronopathy, 19 had small cell lung cancer, 4 had breast cancer, and 3 had other neoplasms. There was a striking predominance of females (20:6). Neuropathic symptoms (pain, paresthesia, sensory loss) were asymmetric at onset, with a predilection for the upper limbs; in three patients, symptoms were confined to the arms. Electrophysiologic testing revealed absent sensory responses and normal or minimally altered motor responses. Slightly more than half the patients had associated autonomic, cerebellar, or cerebral abnormalities. In some patients, treatment of the neoplasm seemed to halt progression of the neuronopathy, but none had neurologic improvement and most continued to worsen, even when the oncologic response was good. Distinguishing between paraneoplastic and nonparaneoplastic sensory neuronopathies can be difficult, but prominent neuropathic pain, neurologic dysfunction involving more than the peripheral sensory system, or an increased cerebrospinal fluid protein value should prompt a careful search for a cancer.",
author = "Chalk, {C. H.} and Windebank, {Anthony John} and Kimmel, {D. W.} and McManis, {P. G.}",
year = "1992",
language = "English (US)",
volume = "19",
pages = "346--351",
journal = "Canadian Journal of Neurological Sciences",
issn = "0317-1671",
publisher = "Canadian Journal of Neurological Sciences",
number = "3",

}

TY - JOUR

T1 - The distinctive clinical features of paraneoplastic sensory neuronopathy

AU - Chalk, C. H.

AU - Windebank, Anthony John

AU - Kimmel, D. W.

AU - McManis, P. G.

PY - 1992

Y1 - 1992

N2 - A 15-year experience with paraneoplastic sensory neuronopathy at the Mayo Clinic is reviewed. Of 26 patients with paraneoplastic sensory neuronopathy, 19 had small cell lung cancer, 4 had breast cancer, and 3 had other neoplasms. There was a striking predominance of females (20:6). Neuropathic symptoms (pain, paresthesia, sensory loss) were asymmetric at onset, with a predilection for the upper limbs; in three patients, symptoms were confined to the arms. Electrophysiologic testing revealed absent sensory responses and normal or minimally altered motor responses. Slightly more than half the patients had associated autonomic, cerebellar, or cerebral abnormalities. In some patients, treatment of the neoplasm seemed to halt progression of the neuronopathy, but none had neurologic improvement and most continued to worsen, even when the oncologic response was good. Distinguishing between paraneoplastic and nonparaneoplastic sensory neuronopathies can be difficult, but prominent neuropathic pain, neurologic dysfunction involving more than the peripheral sensory system, or an increased cerebrospinal fluid protein value should prompt a careful search for a cancer.

AB - A 15-year experience with paraneoplastic sensory neuronopathy at the Mayo Clinic is reviewed. Of 26 patients with paraneoplastic sensory neuronopathy, 19 had small cell lung cancer, 4 had breast cancer, and 3 had other neoplasms. There was a striking predominance of females (20:6). Neuropathic symptoms (pain, paresthesia, sensory loss) were asymmetric at onset, with a predilection for the upper limbs; in three patients, symptoms were confined to the arms. Electrophysiologic testing revealed absent sensory responses and normal or minimally altered motor responses. Slightly more than half the patients had associated autonomic, cerebellar, or cerebral abnormalities. In some patients, treatment of the neoplasm seemed to halt progression of the neuronopathy, but none had neurologic improvement and most continued to worsen, even when the oncologic response was good. Distinguishing between paraneoplastic and nonparaneoplastic sensory neuronopathies can be difficult, but prominent neuropathic pain, neurologic dysfunction involving more than the peripheral sensory system, or an increased cerebrospinal fluid protein value should prompt a careful search for a cancer.

UR - http://www.scopus.com/inward/record.url?scp=0026655735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026655735&partnerID=8YFLogxK

M3 - Article

VL - 19

SP - 346

EP - 351

JO - Canadian Journal of Neurological Sciences

JF - Canadian Journal of Neurological Sciences

SN - 0317-1671

IS - 3

ER -